Odborné publikace

Publikace v impaktovaných periodicích 2024

1.    MUSTO, Pellegrino, Jon SALMANTON-GARCIA, Nicola SGHERZA, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry.
Hematological Oncology. Hoboken: WILEY-BLACKWELL, 2024, roč. 42, č. 1, s. 1-15. ISSN 0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.3240. 
Impact factor: 3.300 v roce 2023

2.    HORŇÁK, Tomáš, Jiří MAYER, Petra ČIČÁTKOVÁ, et al. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
American Journal of Hematology. Hoboken: Wiley-Blackwell, 2024, roč. 99, č. 4, s. 763-766. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.27229.  
Impact factor: 10.100 v roce 2023

3.    SESTAKOVA, Sarka, Cyril SALEK, David KUNDRAT, et al. MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia.
CLINICAL EPIGENETICS. LONDON: BMC, 2024, roč. 16, č. 1, s. 1-12. ISSN 1868-7075. Dostupné z: https://dx.doi.org/10.1186/s13148-024-01625-x.  
Impact factor: 4.800 v roce 2023

4.    PERUSINI, Maria Agustina, Daniela ŽÁČKOVÁ, TaeHyung KIM, et al. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.
Blood advances. AMSTERDAM: ELSEVIER, 2024, roč. 8, č. 10, s. 2361-2372. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2023012127.  
Impact factor: 7.400 v roce 2023

5.    PRATZ, Keith W, Brian A JONAS, Vinod PULLARKAT, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
American Journal of Hematology. Hoboken: Wiley-Blackwell, 2024, roč. 99, č. 4, s. 615-624. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.27246. 
Impact factor: 10.100 v roce 2023

6.    ZEMAN, David, Martin ŠTORK, Lenka ŠVANCAROVÁ, et al. Isoelectric focusing followed by affinity immunoblotting to detect monoclonal free light chains in monoclonal gammopathies: Comparison with immunofixation electrophoresis and free light chain ratio.
Annals of Clinical Biochemistry. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2024, roč. 61, č. 4, s. 291-302. ISSN 0004-5632. Dostupné z: https://dx.doi.org/10.1177/00045632231221439.  
Impact factor: 2.100 v roce 2023

7.    LAHMER, Tobias, Jon SALMANTON-GARCIA, Francesco MARCHESI, et al.
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Infection. HEIDELBERG: Springer, 2024, roč. 52, č. 3, s. 1125-1141. ISSN 0300-8126. Dostupné z: https://dx.doi.org/10.1007/s15010-023-02169-7. 
Impact factor: 5.400 v roce 2023

8.    LUEBKE, Johannes, Alicia SCHMID, Deborah CHRISTEN, et al. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.
Blood advances. AMSTERDAM: ELSEVIER, 2024, roč. 8, č. 11, s. 2890-2900. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2024012756.  
Impact factor: 7.400 v roce 2023

9.    LIPOVÝ, Břetislav, Martin HLADÍK, Kateřina VYKLICKÁ, et al. Rare multi-fungal sepsis: a case of triple-impact immunoparalysis.
Folia microbiologica. Praha: Mikrobiologický ústav Praha AV ČR, 2024, roč. 69, č. 4, s. 903-911. ISSN 0015-5632. Dostupné z: https://dx.doi.org/10.1007/s12223-024-01165-0.  
Impact factor: 2.400 v roce 2023

10.    HOCHHAUS, Andreas, Jianxiang WANG, Dong-Wook KIM, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
New England Journal of Medicine. Waltham: Massachussetts Medical Society, 2024, roč. 391, č. 10, s. 1-14. ISSN 0028-4793. Dostupné z: https://dx.doi.org/10.1056/NEJMoa2400858.  
Impact factor: 96.300 v roce 2023

11.    FRIČ, Dominik, Martin ŠTORK, Ivanna BOICHUK, et al. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.
European Journal of Haematology. Hoboken: Wiley-Blackwell, 2024, roč. 113, č. 6, s. 810-816. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.14292. 
Impact factor: 2.300 v roce 2023

12.    TRIZULJAK, Jakub, Paulína LIKAVCOVÁ, Kateřina STAŇO KOZUBÍK, et al. Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5’UTR variants in three-generational pedigree.
Platelets. PHILADELPHIA: TAYLOR & FRANCIS INC, 2024, roč. 35, č. 1, s. 1-6. ISSN 0953-7104. Dostupné z: https://dx.doi.org/10.1080/09537104.2024.2388103.  
Impact factor: 2.500 v roce 2023

13.    CHATZIKONSTANTINOU, Thomas, Lydia SCARFO, Eva MINGA, et al. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
HemaSphere. Hoboken: Wiley, 2024, roč. 8, č. 9, s. 1-7. ISSN 2572-9241. Dostupné z: https://dx.doi.org/10.1002/hem3.70004. 
Impact factor: 11.900 v roce 2023

14.    SALMANTON-GARCIA, Jon, Francesco MARCHESI, Francesca FARINA et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
EClinicalMedicine. AMSTERDAM: ELSEVIER, 2024, roč. 74, May 2024, s. 1-20. ISSN 2589-5370. Dostupné z: https://dx.doi.org/10.1016/j.eclinm.2024.102553. 
Impact factor: 9.600 v roce 2023

15.    LORUSSO, Domenica, Yang XIANG, Kosei HASEGAWA, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. New York: Elsevier Science Inc., 2024, roč. 404, č. 10460, s. 1321-1332. ISSN 0140-6736. Dostupné z: https://dx.doi.org/10.1016/S0140-6736(24)01808-7.  
Impact factor: 98.400 v roce 2023

16.    PRESL, Jiri, Pavel HAVELKA, Vít WEINBERGER, et al. The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study.
Cancers. BASEL: MDPI, 2024, roč. 16, č. 21, s. 1-12. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers16213566. 
Impact factor: 4.500 v roce 2023

17.    SLABÁ, Kateřina, Petra POKORNÁ, Robin JUGAS, et al. Diagnostic efficacy and clinical utility of whole-exome sequencing in Czech pediatric patients with rare and undiagnosed diseases.
SCIENTIFIC REPORTS. BERLIN: NATURE PORTFOLIO, 2024, roč. 14, č. 1, s. 1-11. ISSN 2045-2322. Dostupné z: https://dx.doi.org/10.1038/s41598-024-79872-4. 
Impact factor: 3.800 v roce 2023

18.    ROHAN, Tomáš, Petr HLOŽANKA, Marek DOSTÁL, et al. Significance of F-18 FDG PET/MRI in the search for the etiology of inflammation of unclear origin and fever of unknown origin.
European journal of radiology. Ireland: Elsevier Science Ireland Ltd, 2024, roč. 171, February 2024, s. 1-6. ISSN 0720-048X. Dostupné z: https://dx.doi.org/10.1016/j.ejrad.2023.111281. 
Impact factor: 3.200 v roce 2023

19.    SVOZILOVÁ, Hana, Lucy VOJTOVA, Jana MATULOVA, et al. In vitro culture of leukemic cells in collagen scaffolds and carboxymethyl cellulose-polyethylene glycol gel.
PeerJ. LONDON: PEERJ INC, 2024, roč. 12, December 2024, s. 1-30. ISSN 2167-8359. Dostupné z: https://dx.doi.org/10.7717/peerj.18637. 
Impact factor: 2.300 v roce 2023

20.    JOSE, Luis Pinana, Gloria TRIDELLO, Alienor XHAARD, et al. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation.
JOURNAL OF INFECTIOUS DISEASES. CARY: OXFORD UNIV PRESS INC, 2024, roč. 229, č. 1, s. 83-94. ISSN 0022-1899. Dostupné z: https://dx.doi.org/10.1093/infdis/jiad268. 
Impact factor: 5.000 v roce 2023

21.    POLAKOVA, Katerina Machova, Ali ALBEER, Vaclava POLIVKOVA, et al. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia. London: Nature Publishing Group, 2024, roč. 38, č. 2, s. 318-325. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-023-02109-2.  
Impact factor: 12.800 v roce 2023

22.    SOBAS, Marta, Wanda KNOPINSKA-POSLUSZNY, Beata PIATKOWSKA-JAKUBAS, et al. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Annals of hematology. New York: Springer Verlag, 2024, roč. 103, č. 2, s. 451-461. ISSN 0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-023-05582-y.  
Impact factor: 3.000 v roce 2023

23.    POTT, Christiane, Vindi JURINOVIC, Judith TROTMAN, et al. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024, roč. 42, č. 5, s. 1-13. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.23.00838. 
Impact factor: 42.100 v roce 2023

24.    BORDINI, Jessica, Chiara LENZI, Michela FRENQUELLI et al. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.
Leukemia. London: Nature Publishing Group, 2024, roč. 38, č. 6, s. 1287-1298. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02236-4.  
Impact factor: 12.800 v roce 2023

25.    PÁLOVÁ, Hana, Anirban DAS, Petra POKORNÁ et al. Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome.
NPJ PRECISION ONCOLOGY. Belin: NATURE PORTFOLIO, 2024, roč. 8, č. 1, s. 1-9. ISSN 2397-768X. Dostupné z: https://dx.doi.org/10.1038/s41698-024-00597-8.  
Impact factor: 6.800 v roce 2023

26.    POUR, Luděk, Monika SZAREJKO, Jelena BILA, et al. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2024, roč. 109, č. 3, s. 895-905. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2023.283509. 
Impact factor: 8.200 v roce 2023

27.    SPANJAART, Anne Mea, Per LJUNGMAN, Gloria TRIDELLO, et al. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.
Leukemia. London: SPRINGERNATURE, 2024, roč. 38, č. 9, s. 1985-1991. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02336-1. 
Impact factor: 12.800 v roce 2023

28.    SCHJESVOLD, Fredrik H, Heinz LUDWIG, Sossana DELIMPASI et al. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2024, roč. 109, č. 7, s. 2331-2336. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2023.284635.  
Impact factor: 8.200 v roce 2023

29.    JURECKOVA, Katerina, Marketa NYKRYNOVA, Eva SLANINOVA, et al. Cultivation driven transcriptomic changes in the wild-type and mutant strains of Rhodospirillum rubrum.
Computational and Structural Biotechnology Journal. AMSTERDAM: Elsevier, 2024, roč. 23, December 2024, s. 2681-2694. ISSN 2001-0370. Dostupné z: https://dx.doi.org/10.1016/j.csbj.2024.06.023. 
Impact factor: 4.500 v roce 2023

30.    ÇELIKER, Canan, Štefan ZELENÁK, Samuel LIETAVA, et al. Generation of human induced pluripotent stem cell lines from patients with a RYR2 gene variant c.14201A>G (p.Y4734C): Implications for idiopathic ventricular fibrillation and catecholaminergic polymorphic ventricular tachycardia.
Stem cell research. Amsterdam: Elsevier, 2024, roč. 81, December 2024, s. 1-5. ISSN 1873-5061. Dostupné z: https://dx.doi.org/10.1016/j.scr.2024.103541.  
Impact factor: 0.800 v roce 2023

31.    GEISSLER, Klaus, Zdenek KORISTEK, del Castillo Teresa BERNAL, et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
British journal of haematology. Hoboken: Wiley-Blackwell, 2024, roč. 205, č. 5, s. 1-12. ISSN 0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.19741.  
Impact factor: 5.100 v roce 2023

32.    TROTMAN, Judith, Pier Luigi ZINZANI, Yuqin SONG, et al. Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
Current medical research and opinion. Oxon: Taylor & Francis, 2024, roč. 40, č. 11, s. 1863-1871. ISSN 0300-7995. Dostupné z: https://dx.doi.org/10.1080/03007995.2024.2409837. 
Impact factor: 2.400 v roce 2023

33.    VILLA, Matteo, Geeta G SHARMA, Federica MALIGHETTI et al. Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
British journal of cancer. LONDON: NATURE PUBLISHING GROUP, 2024, roč. 131, č. 11, s. 1781-1795. ISSN 0007-0920. Dostupné z: https://dx.doi.org/10.1038/s41416-024-02881-7. 
Impact factor: 6.400 v roce 2023

34.    BAUMGARTNER, Daniel, Zuzana MUŠOVÁ, Jana ZÍDKOVÁ, et al. Genetic Landscape of Amyotrophic Lateral Sclerosis in Czech Patients.
Journal of Neuromuscular Diseases. AMSTERDAM: IOS PRESS, 2024, roč. 11, č. 5, s. 1-14. ISSN 2214-3599. Dostupné z: https://dx.doi.org/10.3233/JND-230236.  
Impact factor: 3.200 v roce 2023

35.    ŽÁČKOVÁ, Daniela, Lukáš SEMERÁD, Edgar FABER, et al.
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Leukemia. LONDON: SPRINGERNATURE, 2024, roč. 38, č. 4, s. 893-897. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02215-9.  
Impact factor: 12.800 v roce 2023

36.    KOBLÍŽKOVÁ, Michaela, Petra BRETOVÁ, Michal FELSINGER et al. Faktory zvyšující riziko malignity při nálezu endometriálního polypu v ultrazvukovém obraze.
Česká gynekologie-Czech Gynecology. Praha: Nakladatelské středisko ČLS JEP, 2024, roč. 89, č. 1, s. 44-51. ISSN 1210-7832. Dostupné z: https://dx.doi.org/10.48095/cccg202444. 
Impact factor: 0.500 v roce 2023

37.    BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, et al. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia. London: Nature Publishing Group, 2024, roč. 38, č. 5, s. 1072-1080. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02204-y.  
Impact factor: 12.800 v roce 2023

38.    PATAKOVA, Petra, Maryna VASYLKIVSKA, Karel SEDLAR, et al. Whole genome sequencing and characterization of Pantoea agglomerans DBM 3797, endophyte, isolated from fresh hop (Humulus lupulus L.).
Frontiers in Microbiology. Switzerland: Frontiers Research Foundation, 2024, roč. 15, February 2024, s. 1-15. ISSN 1664-302X. Dostupné z: https://dx.doi.org/10.3389/fmicb.2024.1305338.  
Impact factor: 4.000 v roce 2023

39.    PANOVSKÁ, Anna, Pavel ZAK, Tereza JURKOVA, et al. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Hematological Oncology. Hoboken: WILEY-BLACKWELL, 2024, roč. 42, č. 3, s. 1-9. ISSN 0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.3280. 
Impact factor: 3.300 v roce 2023
Podíly spolupracujících pracovišť MU: Lékařská fakulta: 70%, Středoevropský technologický institut: 30%

40.    MAKKER, Vicky, Jose Alejandro PEREZ-FIDALGO, Giorgio VALABREGA, et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Gynecologic Oncology. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2024, roč. 185, June 2024, s. 202-211. ISSN 0090-8258. Dostupné z: https://dx.doi.org/10.1016/j.ygyno.2024.05.016.  
Impact factor: 4.500 v roce 2023

41.    EFFICACE, Fabio, Francois-Xavier MAHON, Johan RICHTER, et al. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Leukemia. London: Nature Publishing Group, 2024, roč. 38, č. 8, s. 1722-1730. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02341-4.  
Impact factor: 12.800 v roce 2023

42.    CRHA, Tomáš, Vít WEINBERGER, Luboš MINÁŘ, et al. Operační léčba recidivujících gynekologických zhoubných nádorů.
Ceska Gynekologie-Czech Gynaecology. PRAGUE: NAKLADATELSKE STREDISKO C L S J E PURKYNE, 2024, roč. 89, č. 4, s. 309-318. ISSN 1210-7832. Dostupné z: https://dx.doi.org/10.48095/cccg2024309. 
Impact factor: 0.500 v roce 2023

43.    HAGERSTRAND, Daniel, Blaz ODER, Diego CORTESE, et al. The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
Leukemia. LONDON: SPRINGERNATUR, 2024, roč. 38, č. 11, s. 2429-2442. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02379-4.  
Impact factor: 12.800 v roce 2023

44.    MURONOVA, Ludmila, Ondrej SOUCEK, David ZIHALA, et al. Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.
European Journal of Haematology. Hoboken: Wiley-Blackwell, 2024, roč. 114, č. 11, s. 1-9. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.14316.  
Impact factor: 2.300 v roce 2023

45.    BROWN, Jennifer R, Barbara EICHHORST, Nicole LAMANNA et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
Blood. Washington DC, USA: American Society of Hematology, 2024, roč. 144, č. 26, s. 2706-2717. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2024024667. 
Impact factor: 21.100 v roce 2023

46.    EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2024, roč. 65, č. 2, s. 199-208. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2023.2280886. 
Impact factor: 2.200 v roce 2023

47.    KURUCOVÁ, Terézia, Kamila RÉBLOVÁ, Pavlína JANOVSKÁ, et al. Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single-cell RNA sequencing.
Molecular oncology. Hoboken: Wiley, 2024, roč. 18, č. 10, s. 2541-2553. ISSN 1574-7891. Dostupné z: https://dx.doi.org/10.1002/1878-0261.13663. 
Impact factor: 5.000 v roce 2023

48.    KUTER, David J, Jiří MAYER, Merlin EFRAIM, et al. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Blood advances. AMSTERDAM: ELSEVIER, 2024, roč. 8, č. 7, s. 1715-1724. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2023012044. 
Impact factor: 7.400 v roce 2023

49.    MALČÍKOVÁ, Jitka, Šárka PAVLOVÁ, Panagiotis BALIAKAS, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
Leukemia. London: Nature Publishing Group, 2024, roč. 38, č. 7, s. 1455-1468. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02267-x.  
Impact factor: 12.800 v roce 2023

50.    KILADJIAN, Jean-Jacques, Francisca Ferrer MARIN, Haifa Kathrin AL-ALI, ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Annals of hematology. New York: Springer Verlag, 2024, roč. 103, č. 7, s. 2299-2310. ISSN 0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-024-05665-4.  
Impact factor: 3.000 v roce 2023

51.    WEINBERGEROVÁ, Barbora, Jiří MAYER, Tomas KABUT, et al. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
British journal of haematology. Hoboken: Wiley-Blackwell, 2024, roč. 205, č. 5, s. 1746-1750. ISSN 0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.19670.  
Impact factor: 5.100 v roce 2023

52.    STAMATOPOULOS, Kostas, Šárka PAVLOVÁ, Othman AL-SAWAF et al. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities.
HemaSphere. Philadelphia: Lippincott Williams & Wilkins, 2024, roč. 8, č. 7, s. 1-12. ISSN 2572-9241. Dostupné z: https://dx.doi.org/10.1002/hem3.113. 
Impact factor: 11.900 v roce 2023

53.    MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024, roč. 42, č. 16, s. 1-11. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.23.01647.  
Impact factor: 42.100 v roce 2023

54.    LUCINI, Chantal, Klara OBROVA, Isabella KRICKL, et al. Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study.
JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2024, roč. 17, č. 1, s. 1-6. ISSN 1756-8722. Dostupné z: https://dx.doi.org/10.1186/s13045-024-01583-0. 
Impact factor: 29.900 v roce 2023

55.    ŠTORK, Martin, Eva ONDROUŠKOVÁ, Michaela BOHÚNOVÁ, et al. Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.
Blood Cancer Journal. LONDON: SPRINGERNATURE, 2024, roč. 14, č. 1, s. 1-3. ISSN 2044-5385. Dostupné z: https://dx.doi.org/10.1038/s41408-024-01131-6.  
Impact factor: 12.900 v roce 2023

56.    RASLOVA, Katarina, Viera DONICOVA, Katarina GONOVA, et al. Detecting familial hypercholesterolemia: An observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia.
Journal of Clinical Lipidology. New York: ELSEVIER SCIENCE INC, 2024, roč. 18, č. 4, s. "e537"-"e547", 11 s. ISSN 1933-2874. Dostupné z: https://dx.doi.org/10.1016/j.jacl.2024.03.009. 
Impact factor: 3.600 v roce 2023

57.    SYKOROVA, Alice, František FOLBER, Kamila POLGAROVA, et al. Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Cancer Medicine. Hoboken: Wiley, 2024, roč. 13, č. 17, s. 1-15. ISSN 2045-7634. Dostupné z: https://dx.doi.org/10.1002/cam4.70138.  
Impact factor: 2.900 v roce 2023

58.    BELOHLAVKOVA, Petra, Daniela ŽÁČKOVÁ, Hana KLAMOVA, et al. Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.
Cancer Medicine. Hoboken: John Wiley & Sons Ltd., 2024, roč. 13, č. 17, s. 1-10. ISSN 2045-7634. Dostupné z: https://dx.doi.org/10.1002/cam4.70158.  
Impact factor: 2.900 v roce 2023

59.    POKORNÁ, Petra, Hana PÁLOVÁ, Soňa ADAMCOVÁ, et al. Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology.
Laboratory Investigation. NEW YORK: ELSEVIER, 2024, roč. 104, č. 12, s. 1-12. ISSN 0023-6837. Dostupné z: https://dx.doi.org/10.1016/j.labinv.2024.102161.  
Impact factor: 5.100 v roce 2023

60.    AIELLO, Tommaso Francesco, Jon SALMANTON-GARCIA, Francesco MARCHESI et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry.
Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2024, roč. 109, č. 8, s. 2693-2700. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2023.284678. 
Impact factor: 8.200 v roce 2023

61.    HUGHES, Timothy P, Giuseppe SAGLIO, Jan GEISSLER, et al. Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.
JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2024, roč. 17, č. 1, s. 1-12. ISSN 1756-8722. Dostupné z: https://dx.doi.org/10.1186/s13045-024-01642-6.  
Impact factor: 29.900 v roce 2023

62.    OH, Stephen T, Srdan VERSTOVSEK, Vikas GUPTA, et al. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
eJHaem. Hoboken: Wiley, 2024, roč. 5, č. 1, s. 105-116. ISSN 2688-6146. Dostupné z: https://dx.doi.org/10.1002/jha2.854.  

63.    HOFERKOVÁ, Eva, Václav ŠEDA, Soňa CESNÁRIKOVÁ, et al. Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug.
Leukemia. LONDON: SPRINGERNATURE, 2024, roč. 38, č. 8, s. 1-13. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02284-w.  
Impact factor: 12.800 v roce 2023

64.    DEB, Rahul, Marcelo D. T. TORRES, Miroslav BOUDNÝ, et al. Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities.
Journal of Medicinal Chemistry. Washington: American Chemical Society, 2024, roč. 67, č. 16, s. 14040-14061. ISSN 0022-2623. Dostupné z: https://dx.doi.org/10.1021/acs.jmedchem.4c00912. 
Impact factor: 6.900 v roce 2023

65.    ONDRIŠOVÁ, Laura, Václav ŠEDA, Kryštof HLAVÁČ et al. FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia.
The Journal of Clinical Investigation. MANCHESTER: AMER SOC CLINICAL INVESTIGATION INC, 2024, roč. 134, č. 23, s. 1-17. ISSN 0021-9738. Dostupné z: https://dx.doi.org/10.1172/JCI173770.  
Impact factor: 13.300 v roce 2023

66.    ŠTIKA, Jiří, Michaela PEŠOVÁ, Kateřina STAŇO KOZUBÍK, et al. A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study.
British journal of haematology. Hoboken: Wiley-Blackwell, 2024, roč. 205, č. 6, s. 2450-2458. ISSN 0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.19694. 
Impact factor: 5.100 v roce 2023

67.    NAVRKALOVÁ, Veronika, Karla PLEVOVÁ, Lenka RADOVÁ, et al. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.
British journal of haematology. Hoboken: Wiley-Blackwell, 2024, roč. 204, č. 1, s. 240-249. ISSN 0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.19191.  
Impact factor: 5.100 v roce 2023

68.    DOLNIKOVA, Alexandra, Dmitry KAZANTSEV, Magdalena KLANOVA, et al. Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status.
Blood advances. AMSTERDAM: ELSEVIER, 2024, roč. 8, č. 13, s. 1-12. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2024012906.  
Impact factor: 7.400 v roce 2023

69.    VYHLÍDALOVÁ KOTRBOVÁ, Anna, Kristína GÖMÖRYOVÁ, Antónia MIKULOVÁ, et al. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
Journal of Extracellular Vesicles. Wiley, 2024, roč. 13, č. 3, s. 1-22. ISSN 2001-3078. Dostupné z: https://dx.doi.org/10.1002/jev2.12420.  
Impact factor: 15.500 v roce 2023

70.    CURYLOVÁ, Lucie, Iva ZAMBO, Jakub NERADIL, et al. Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits.
CELLULAR ONCOLOGY. DORDRECHT: SPRINGER, 2024, roč. 47, č. 6, s. 2317-2334. ISSN 2211-3428. Dostupné z: https://dx.doi.org/10.1007/s13402-024-01020-x.  
Impact factor: 4.900 v roce 2023

 

 

Publikace v impaktovaných periodicích 2023

1.    JELINEK, Tomas, Renata BEZDĚKOVÁ, David ZIHALA, et al.
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2023, roč. 41, č. 7, s. 1383-1393. ISSN 0732-183X. doi:10.1200/JCO.22.01226. 
Impact factor: 45.300 v roce 2022

2.    BROWN, Jennifer, Barbara EICHHORST, Peter HILLMEN, et al.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
New England Journal of Medicine. Waltham: Massachussetts Medical Society, 2023, roč. 388, č. 4, s. 319-332. ISSN 0028-4793. doi:10.1056/NEJMoa2211582. 
Impact factor: 158.500 v roce 2022

3.    PROCHÁZKOVÁ, Dagmar, Romana BORSKÁ, Petr CHRASTINA, et al.
První český pacient s deficitem aminoacylázy 1.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE. CZECH REPUBLIC: CZECH MEDICAL SOC, 2023, roč. 86, č. 1, s. 83-85. ISSN 1210-7859. doi:10.48095/cccsnn202383.
Impact factor: 0.500 v roce 2022

4.    ŠTORK, Martin, Ivan SPICKA, Jakub RADOCHA, et al.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis.
Annals of Hematology. NEW YORK: SPRINGER, 2023, roč. 102, č. 6, s. 1501-1511. ISSN 0939-5555. doi:10.1007/s00277-023-05188-4.
Impact factor: 3.500 v roce 2022

5.    PULANIC, Drazen, Angelika BATOROVA, Imre BODO, et al.
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Annals of hematology. New York: Springer Verlag, 2023, roč. 102, č. 4, s. 715-727. ISSN 0939-5555. doi:10.1007/s00277-023-05114-8.
Impact factor: 3.500 v roce 2022

6.    HILLMEN, Peter, Barbara EICHHORST, Jennifer R BROWN, et al.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Journal of clinical oncology. United States: LIPPINCOTT WILLIAMS & WILKINS, 2023, roč. 41, č. 5, s. "1035"-"+", 12 s. ISSN 0732-183X. doi:10.1200/JCO.22.00510.
Impact factor: 45.300 v roce 2022

7.    BUSCA, Alessandro, Jon SALMANTON-GARCIA, Francesco MARCHESI, et al.
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.
Frontiers in immunology. LAUSANNE: Frontiers Media S.A., 2023, roč. 14, February 2023, s. 1-9. ISSN 1664-3224. doi:10.3389/fimmu.2023.1125030.
Impact factor: 7.300 v roce 2022

8.    KUBEŠ, Václav, Leoš KŘEN, Filip SOKOL, et al.
Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2023, roč. 37, č. 4, s. 1735-1742. ISSN 0258-851X. doi:10.21873/invivo.13261.
Impact factor: 2.300 v roce 2022

9.    SEKERES, Mikkael A, Pau MONTESINOS, Jan NOVAK, et al.
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Leukemia. London: Nature Publishing Group, 2023, roč. 37, č. 10, s. 2017-2026. ISSN 0887-6924. doi:10.1038/s41375-023-02001-z.
Impact factor: 11.400 v roce 2022

10.    VERSTOVSEK, Srdan, Ruben MESA, Vikas GUPTA, et al.
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Blood advances. AMSTERDAM: ELSEVIER, 2023, roč. 7, č. 14, s. 3582-3591. ISSN 2473-9529. doi:10.1182/bloodadvances.2022009311.
Impact factor: 7.500 v roce 2022

11.    DESAI, Sanjal H, Michael A SPINNER, Andrew M EVENS, et al.
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Blood advances. AMSTERDAM: ELSEVIER, 2023, roč. 7, č. 23, s. 7295-7303. ISSN 2473-9529. doi:10.1182/bloodadvances.2023011205. 
Impact factor: 7.500 v roce 2022

12.    ROSSI, Giuseppe, Jon SALMANTON-GARCIA, Chiara CATTANEO,et al.
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings.
International journal of infectious diseases. OXON: ELSEVIER SCI LTD, 2023, roč. 137, December 2023, s. 98-110. ISSN 1201-9712. doi:10.1016/j.ijid.2023.10.013. 
Impact factor: 8.400 v roce 2022

13.    MAERTENS, Johan, Tom LODEWYCK, J Peter DONNELLY, et al.
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Clinical Infectious Diseases. CARY: OXFORD UNIV PRESS INC, 2023, roč. 76, č. 4, s. 674-682. ISSN 1058-4838. doi:10.1093/cid/ciac623.
Impact factor: 11.800 v roce 2022

14.    FEDOROVÁ, Veronika, Kateřina AMRUZ ČERNÁ, Jan OPPELT, et al.
MicroRNA Profiling of Self-Renewing Human Neural Stem Cells Reveals Novel Sets of Differentially Expressed microRNAs During Neural Differentiation In Vitro.
Stem Cell Reviews and Reports. NEW YORK: SPRINGER, 2023, roč. 19, č. 5, s. 1524-1539. ISSN 2629-3269. doi:10.1007/s12015-023-10524-2.
Impact factor: 4.800 v roce 2022

15.    ŠŤASTNÁ, Nela, Kristián BRAT, Lukáš HOMOLA, Audun OS a Dagmar BRANČÍKOVÁ.
Increasing incidence rate of breast cancer in cystic fibrosis-relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens.
Orphanet Journal of Rare Diseases. London: England, 2023, roč. 18, č. 1, s. 1-7. ISSN 1750-1172. doi:10.1186/s13023-023-02671-z. 
Impact factor: 3.700 v roce 2022

16.    VENTRUBA, Tomáš, Michal JEŠETA, Luboš MINÁŘ, Jindřich VOMELA, et al.
Czech Women’s Point of Views on Immediate Breast Reconstruction after Mastectomy due to BRCA Gene Mutation or Breast Cancer.
Healthcare. Basel: MDPI, 2023, roč. 11, č. 12, s. 1-15. ISSN 2227-9032. doi:10.3390/healthcare11121755. 
Impact factor: 2.800 v roce 2022

17.    ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ a Miroslav PENKA.
JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION. AMSTERDAM: IOS PRESS, 2023, roč. 84, č. 4, s. 359-368. ISSN 1386-0291. doi:10.3233/CH-221678. 
Impact factor: 2.100 v roce 2022

18.    ECKARDT, Jan-Niklas, Sebastian STASIK, Christoph ROLLIG, et al.
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
Blood Cancer Journal. LONDON: NATURE PUBLISHING GROUP, 2023, roč. 13, č. 1, s. 1-9. ISSN 2044-5385. doi:10.1038/s41408-023-00790-1. 
Impact factor: 12.800 v roce 2022

19.    BEZDÍČEK, Matěj, Jana HANSLIKOVA, Marketa NYKRYNOVA, et al.
New Multilocus Sequence Typing Scheme for Enterococcus faecium Based on Whole Genome Sequencing Data.
Microbiology Spectrum. WASHINGTON: AMER SOC MICROBIOLOGY, 2023, roč. 11, č. 4, s. 1-9. ISSN 2165-0497. doi:10.1128/spectrum.05107-22.
Impact factor: 3.700 v roce 2022

20.    VALENT, Peter, Karin HARTMANN, Patrizia BONADONNA, et al.
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. AMSTERDAM: ELSEVIER, 2023, roč. 11, č. 6, s. 1706-1717. ISSN 2213-2198. doi:10.1016/j.jaip.2023.02.021. 
Impact factor: 9.400 v roce 2022

21.    KOVÁCSOVÁ, Flóra, František FOLBER, Barbora WEINBERGEROVÁ, et al.
Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use.
Annals of hematology. New York: Springer Verlag, 2023, roč. 102, č. 12, s. 3587-3591. ISSN 0939-5555. doi:10.1007/s00277-023-05479-w. info
Impact factor: 3.500 v roce 2022

22.    SALMANTON-GARCIA, Jon, Francesco MARCHESI, da Silva Maria GOMES, et al.
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
EClinicalMedicine. AMSTERDAM: ELSEVIER, 2023, roč. 58, April 2023, s. 1-19. ISSN 2589-5370. doi:10.1016/j.eclinm.2023.101939.
Impact factor: 15.100 v roce 2022

23.    EID, Michal, Jakub FOUKAL, Dana SOCHOROVÁ, et al.
Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.
Cancer Medicine. Hoboken: John Wiley & Sons Ltd., 2023, roč. 12, č. 13, s. 13942-13957. ISSN 2045-7634. doi:10.1002/cam4.6010.
Impact factor: 4.000 v roce 2022

24.    DUFKOVÁ, Kristýna, Matěj BEZDÍČEK, Markéta NYKRÝNOVÁ, et al.
Rapid Identification of Pseudomonas aeruginosa International High-Risk Clones Based on High-Resolution Melting Analysis.
Microbiology Spectrum. WASHINGTON: AMER SOC MICROBIOLOGY, 2023, roč. 11, č. 1, s. 1-9. ISSN 2165-0497. doi:10.1128/spectrum.03571-22.
Impact factor: 3.700 v roce 2022

25.    WEINBERGEROVÁ, Barbora, Martin ČERŇAN, Tomáš KABUT, et al.
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience.
Haematologica. PAVIA: FERRATA STORT, 2023, roč. 108, č. 10, s. 2826-2829. ISSN 0390-6078. doi:10.3324/haematol.2022.282263. 
Impact factor: 10.100 v roce 2022

26.    KENNEDY, Vanessa E, Cecelia PERKINS, et al.
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
Blood advances. AMSTERDAM: ELSEVIER, 2023, roč. 7, č. 9, s. 1713-1724. ISSN 2473-9529. doi:10.1182/bloodadvances.2022008292.
Impact factor: 7.500 v roce 2022

27.    KILADJIAN, Jean-Jacques, Alessandro M VANNUCCHI, Aaron T GERDS, et al.
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
HemaSphere. Philadelphia: Lippincott Williams & Wilkins, 2023, roč. 7, č. 11, s. 1-15. ISSN 2572-9241. doi:10.1097/HS9.0000000000000963. 
Impact factor: 6.600 v roce 2022

28.    KLINCOVÁ, Martina, Dagmar ŠTĚPÁNKOVÁ, Ivana SCHRÖDEROVÁ, et al.
20 let diagnostiky maligní hypertermie v České a Slovenské republice.
ANESTEZIOLOGIE A INTENZIVNI MEDICINA. CZECH REPUBLIC: NAKLADATELSKE STREDISKO C L S J E PURKYNE, 2023, roč. 34, č. 3, s. 103-109. ISSN 1214-2158. doi:10.36290/aim.2023.045.
Impact factor: 0.100 v roce 2022

29.    LUEBKE, Johannes, Juliana SCHWAAB, Deborah CHRISTEN, et al.
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. AMSTERDAM: ELSEVIER, 2023, roč. 11, č. 2, s. 581-595. ISSN 2213-2198. doi:10.1016/j.jaip.2022.10.051.
Impact factor: 9.400 v roce 2022

30.    CHATZIKONSTANTINOU, Thomas, Lydia SCARFÒ, Georgios KARAKATSOULIS, et al.
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
Blood advances. AMSTERDAM: ELSEVIER, 2023, roč. 7, č. 11, s. 2645-2655. ISSN 2473-9529. doi:10.1182/bloodadvances.2022009578.
Impact factor: 7.500 v roce 2022

32.    ANGENENDT, Linus, Christoph ROELLIG, Pau MONTESINOS, et al.
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.
Blood. Washington DC, USA: American Society of Hematology, 2023, roč. 141, č. 4, s. 433-435. ISSN 0006-4971. doi:10.1182/blood.2022018582.
Impact factor: 20.300 v roce 2022

33.    KNIGHT, Andrea, Martin PISKÁČEK, Michal JURAJDA, et al.
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Cancer immunology, immunotherapy. NEW YORK: SPRINGER, 2023, roč. 72, č. 5, s. 1209-1224. ISSN 0340-7004. doi:10.1007/s00262-022-03312-3.
Impact factor: 5.800 v roce 2022

34.    LJUNGMAN, Per, Gloria TRIDELLO, Jose Luis PINANA, et al.
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.
Frontiers in immunology. LAUSANNE: Frontiers Media S.A., 2023, roč. 14, March 2023, s. 1-11. ISSN 1664-3224. doi:10.3389/fimmu.2023.1125824. 
Impact factor: 7.300 v roce 2022

35.    NOORT, Sanne, van Oosterwijk JOLIEKE, Jing MA, et al.
Analysis of rare driving events in pediatric acute myeloid leukemia.
haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2023, roč. 108, č. 1, s. 48-60. ISSN 0390-6078. doi:10.3324/haematol.2021.280250. 
Impact factor: 10.100 v roce 2022

36.    TOPP, Max, Monika DLUGOSZ-DANECKA, Aleksander B SKOTNICKI, et al.
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
Trials. LONDON: BMC, 2023, roč. 24, č. 1, s. 1-11. ISSN 1745-6215. doi:10.1186/s13063-022-06982-7. 
Impact factor: 2.500 v roce 2022

37.    KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ a Jiří MAYER.
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience.
Bone Marrow Transplantation. LONDON: SPRINGERNATURE, 2023, roč. 58, č. 11, s. 1229-1236. ISSN 0268-3369. doi:10.1038/s41409-023-02081-6. 
Impact factor: 4.800 v roce 2022

38.    ZINZANI, Pier Luigi, Jiří MAYER, Christopher R FLOWERS, et al.
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Journal of Clinical Oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2023, roč. 41, č. 33, s. 5107-5117, 13 s. ISSN 0732-183X. doi:10.1200/JCO.23.00775.
Impact factor: 45.300 v roce 2022

39.    ECKARDT, Jan-Niklas, Sebastian STASIK, Christoph ROELLIG, et al.
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Leukemia. London: Nature Publishing Group, 2023, roč. 37, č. 12, s. 2395-2403. ISSN 0887-6924. doi:10.1038/s41375-023-02061-1. 
Impact factor: 11.400 v roce 2022

40.    ROMANOVÁ, Gabriela, Petr SMEJKAL, Petra OVESNÁ, et al.
Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data).
Annals of hematology. New York: Springer Verlag, 2023, roč. 102, č. 11, s. 3261-3270. ISSN 0939-5555. doi:10.1007/s00277-023-05453-6.
Impact factor: 3.500 v roce 2022

41.    ECKARDT, Jan-Niklas, Christoph ROELLIG, Klaus METZELER, et al.
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles.
Communications Medicine. LONDON: SPRINGERNATURE, 2023, roč. 3, č. 1, s. 1-13. ISSN 2730-664X. doi:10.1038/s43856-023-00298-6.

42.    SALMANTON-GARCÍA, Jon, Francesco MARCHESI, Philipp KOEHLER, et al.
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
International Journal of Antimicrobial Agents. AMSTERDAM: ELSEVIER, 2023, roč. 92, č. 4, s. 1-9. ISSN 0924-8579. doi:10.1016/j.ijantimicag.2023.106952. 
Impact factor: 10.800 v roce 2022

43.    TRIZULJAK, Jakub, Jakub DUBEN, Ivona BLAHÁKOVÁ, et al.
Extensive, 3.8 Mb-Sized Deletion of 22q12 in a Patient with Bilateral Schwannoma, Intellectual Disability, Sensorineural Hearing Loss, and Epilepsy.
Molecular Syndromology. Basel: S. Karger, 2023, roč. 14, č. 5, s. 439-448. ISSN 1661-8769. doi:10.1159/000528744.
Impact factor: 1.100 v roce 2022

44.    MANČÍKOVÁ, Veronika, Michaela PEŠOVÁ, Šárka PAVLOVÁ, et al.
Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.
MOLECULAR ONCOLOGY. ENGLAND: WILEY, 2023, roč. 17, č. 1, s. 82-97. ISSN 1574-7891. doi:10.1002/1878-0261.13337. 
Impact factor: 6.600 v roce 2022

 

 

Publikace v impaktovaných periodicích 2022

1.    POKORNÁ, Petra, Giannoula KLEMENT, Alžběta VAŠÍKOVÁ, et al.
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
JCO PRECISION ONCOLOGY. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2022, roč. 6, June 2022, s. 1-7. ISSN 2473-4284. doi:10.1200/PO.21.00525.
Impact factor: 5.479 v roce 2021

2.    ECKARDT, J. N., F. STOLZEL, D. KUNADT, et al.
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2022, roč. 15, č. 1, s. 1-13. ISSN 1756-8722. doi:10.1186/s13045-022-01267-7. 
Impact factor: 23.168 v roce 2021

3.    KAUFMAN, Matthew, Xiao-Jie YAN, Wentian LI, et al.
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia.
Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2022, roč. 12, July 2022, s. 1-12. ISSN 2234-943X. doi:10.3389/fonc.2022.897280. 
Impact factor: 5.738 v roce 2021

4.    POPPOVÁ, Lucie, Šárka PAVLOVÁ, Beatriz GONZALEZ, et al.
Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene.
Epigenetics. Philadelphia: TAYLOR & FRANCIS INC, 2022, roč. 17, č. 12, s. 1628-1635. ISSN 1559-2294. doi:10.1080/15592294.2022.2050004. 
Impact factor: 4.861 v roce 2021

5.    PRATZ, Keith W, Courtney D DINARDO, et al.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, roč. 97, č. 11, s. "E416"-"E419", 4 s. ISSN 0361-8609. doi:10.1002/ajh.26692. 
Impact factor: 13.265 v roce 2021

6.    CATTANEO, Chiara, Jon SALMANTON-GARCIA, Francesco MARCHESI, et al.
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey.
Cancers. Basel: MDPI, 2022, roč. 14, č. 22, s. 1-16. ISSN 2072-6694. doi:10.3390/cancers14225530. 
Impact factor: 6.575 v roce 2021

7.    JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, et al.
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Leukemia. London: Nature Publishing Group, 2022, roč. 36, č. 1, s. 288-291. ISSN 0887-6924. doi:10.1038/s41375-021-01343-w. 
Impact factor: 12.883 v roce 2021

8.    BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Lucie EHRLICHOVÁ, et al.
Cancers. Basel: MDPI, 2022, roč. 14, č. 10, s. 1-13. ISSN 2072-6694. doi:10.3390/cancers14102353.
Impact factor: 6.575 v roce 2021

9.    ŠTINGL, Jan, Julie HYLMAROVÁ, Martina LENGEROVÁ, Jan MALÁSKA a Jan STAŠEK. Cryptococcal Pneumonia: An Unusual Complication in a COVID-19 Patient.
Diagnostics. Basel: MDPI, 2022, roč. 12, č. 8, s. 1-7. ISSN 2075-4418. doi:10.3390/diagnostics12081944.
Impact factor: 3.992 v roce 2021

10.    KLINCOVÁ, Martina, Dagmar ŠTĚPÁNKOVÁ, Ivana SCHRÖDEROVÁ, et al.
Malignant hyperthermia in Czechia and Slovakia.
British Journal of Anaesthesia. OXFORD: ELSEVIER, 2022, roč. 129, č. 2, s. "e41"-"e43", 3 s. ISSN 0007-0912. doi:10.1016/j.bja.2022.04.029.
Impact factor: 11.719 v roce 2021

11.    ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Tomas JELINEK, et al.
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
Biomedicines. Basel: MDPI, 2022, roč. 10, č. 10, s. 1-15. ISSN 2227-9059. doi:10.3390/biomedicines10102535. 
Impact factor: 4.757 v roce 2021

12.    PETER, Barbara, Gregor EISENWORT, Irina SADOVNIK, et al.
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia.
American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, roč. 97, č. 9, s. 1215-1225. ISSN 0361-8609. doi:10.1002/ajh.26650. 
Impact factor: 13.265 v roce 2021

13.    OLBERTOVÁ, Helena, Karla PLEVOVÁ, Šárka PAVLOVÁ, et al.
Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.
BMC Cancer. London: BMC, 2022, roč. 22, č. 1, s. 1-11. ISSN 1471-2407. doi:10.1186/s12885-022-09221-z.
Impact factor: 4.638 v roce 2021

14.    ŠEDOVÁ, Petra, R. D. BROWN, Tomáš BRYNDZIAR, et al.
Treat COVID-19, but Not Only COVID-19: Stroke Matters as Well.
Cerebrovascular Diseases. BASEL: KARGER, 2022, roč. 51, č. 1, s. 52-59. ISSN 1015-9770. doi:10.1159/000517968. 
Impact factor: 3.104 v roce 2021

15.    FOLTA, Adam, Markéta SASINKOVA, Anna ĎURINÍKOVÁ, et al.
Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.
Molecular Biology Reports. DORDRECHT: SPRINGER, 2022, roč. 49, č. 8, s. 8169-8172. ISSN 0301-4851. doi:10.1007/s11033-022-07363-8. 
Impact factor: 2.742 v roce 2021

16.    JANÍKOVÁ, Andrea, Jozef MICHALKA, Renata CHLOUPKOVÁ, et al.
Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL).
Annals of hematology. New York: Springer Verlag, 2022, roč. 101, č. 4, s. 789-798. ISSN 0939-5555. doi:10.1007/s00277-022-04759-1.
Impact factor: 4.030 v roce 2021

17.    WHITE, Helen E, Matthew SALMON, et al.
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
Leukemia. London: Nature Publishing Group, 2022, roč. 36, č. 7, s. 1834-1842. ISSN 0887-6924. doi:10.1038/s41375-022-01607-z. 
Impact factor: 12.883 v roce 2021

18.    VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, et al.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
European Journal of Haematology. Hoboken: Wiley-Blackwell, 2022, roč. 109, č. 2, s. 162-165. ISSN 0902-4441. doi:10.1111/ejh.13784. 
Impact factor: 3.674 v roce 2021

19.    KAYSER, Sabine, Michael KRAMER, David MARTINEZ-CUADRON, et al.
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2022, roč. 107, č. 4, s. 836-843. ISSN 0390-6078. doi:10.3324/haematol.2021.278645.
Impact factor: 11.047 v roce 2021

20.    ZANOTTI, R., M. BONIFACIO, G. LUCCHINI, et al.
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
Leukemia. London: Nature Publishing Group, 2022, roč. 36, č. 2, s. 516-524. ISSN 0887-6924. doi:10.1038/s41375-021-01406-y. 
Impact factor: 12.883 v roce 2021

21.    SALMON, M., H. E. WHITE, Hana ZIZKOVA, et al.
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Leukemia. LONDON: Springer, 2022, roč. 36, č. 7, s. 1879-1886. ISSN 0887-6924. doi:10.1038/s41375-022-01612-2. 
Impact factor: 12.883 v roce 2021

22.    BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, et al.
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations.
HemaSphere. Philadelphia: Lippincott Williams & Wilkins, 2022, roč. 6, č. 4, s. 1-7. ISSN 2572-9241. doi:10.1097/HS9.0000000000000707. 
Impact factor: 8.300 v roce 2021

23.    HORÁK, Ondřej, Martina BUREŠOVÁ, Senad KOLÁŘ, et al.
Next-generation sequencing in children with epilepsy: The importance of precise genotype–phenotype correlation.
EPILEPSY & BEHAVIOR. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2022, roč. 128, March 2022, s. 1-6. ISSN 1525-5050. doi:10.1016/j.yebeh.2022.108564.
Impact factor: 3.337 v roce 2021

24.    NISHIMURA, Jun-ichi, Kiyoshi ANDO, Masayoshi MASUKO, et al.
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.
Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2022, roč. 107, č. 6, s. 1483-1488. ISSN 0390-6078. doi:10.3324/haematol.2020.265868.
Impact factor: 11.047 v roce 2021

25.    MINARIK, Jiri, Jakub RADOCHA, Alexandra JUNGOVA, et al.
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Cancers. Basel: MDPI, 2022, roč. 14, č. 20, s. 1-13. ISSN 2072-6694. doi:10.3390/cancers14205165.
Impact factor: 6.575 v roce 2021

26.    KOUKALOVÁ, Renata, Jiří VAŠINA, Jiří ŠTIKA, Michael DOUBEK a Petr SZTURZ.
Aggressive systemic mastocytosis with diffuse bone marrow (18) F-FDG uptake.
Nuklearmedizin-Nuclear Medicine. Stuttgart: Schattauer GmbH-Verlag Medizin Naturwissenschaften, 2022, roč. 61, č. 01, s. 58-61. ISSN 0029-5566. doi:10.1055/a-1650-9704. 
Impact factor: 2.221 v roce 2021

27.    BAŤALÍK, Ladislav, Katerina FILAKOVA, Ivana RADKOVCOVA, et al.
Cardio-Oncology Rehabilitation and Telehealth: Rationale for Future Integration in Supportive Care of Cancer Survivors.
FRONTIERS IN CARDIOVASCULAR MEDICINE. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč. 9, April 2022, s. 1-11. ISSN 2297-055X. doi:10.3389/fcvm.2022.858334. 
Impact factor: 5.846 v roce 2021

28.    ONDROUŠKOVÁ, Eva, Michaela BOHÚNOVÁ, Kristýna ZÁVACKÁ, et al.
Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations.
Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2022, roč. 12, June 2022, s. 1-11. ISSN 2234-943X. doi:10.3389/fonc.2022.859618.
Impact factor: 5.738 v roce 2021

29.    INFANTE, Maria Stefania, Jon SALMANTON-GARCIA, Ana FERNANDEZ-CRUZ, et al.
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2022, roč. 12, October 2022, s. 1-17. ISSN 2234-943X. doi:10.3389/fonc.2022.992137. 
Impact factor: 5.738 v roce 2021

30.    VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, et al.
Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?
Cancers. Basel: MDPI, 2022, roč. 14, č. 1, s. 1-11. ISSN 2072-6694. doi:10.3390/cancers14010115.
Impact factor: 6.575 v roce 2021

31.    SALEK, Cyril, František FOLBER, Eva FRONKOVA, et al.
Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
British journal of haematology. England: Wiley-Blackwell, 2022, roč. 196, č. 3, s. 706-710. ISSN 0007-1048. doi:10.1111/bjh.17966.
Impact factor: 8.615 v roce 2021

32.    PAGANO, Livio, Jon SALMANTON-GARCÍA, Francesco MARCHESI, et al.
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
Blood. Washington DC, USA: American Society of Hematology, 2022, roč. 139, č. 10, s. 1588-1592. ISSN 0006-4971. doi:10.1182/blood.2021014124. 
Impact factor: 25.476 v roce 2021

33.    KUTER, D. J., M. EFRAIM, Jiří MAYER, et al.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
New England Journal of Medicine. Waltham: Massachussetts Medical Society, 2022, roč. 386, č. 15, s. 1421-1431. ISSN 0028-4793. doi:10.1056/NEJMoa2110297. 
Impact factor: 176.079 v roce 2021

34.    DREYLING, Martin, Marc ANDRE, Nicola GOKBUGET, et al.
The EHA Research Roadmap: Malignant Lymphoid Diseases.
HemaSphere. Philadelphia: Lippincott Williams & Wilkins, 2022, roč. 6, č. 6, s. 1-18. ISSN 2572-9241. doi:10.1097/HS9.0000000000000726.
Impact factor: 8.300 v roce 2021

35.    BLENNOW, Ola, Jon SALMANTON-GARCIA, Piotr NOWAK, et al.
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.
American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, roč. 97, č. 8, s. "E312"-"E317", 6 s. ISSN 0361-8609. doi:10.1002/ajh.26626.
Impact factor: 13.265 v roce 2021

36.    BRYNDZIAR, Tomáš, Dominika MATYSKOVÁ, Petra ŠEDOVÁ, et al.
Predictors of Short- and Long-Term Mortality in Ischemic Stroke: A Community-Based Study in Brno, Czech Republic.
Cerebrovascular Diseases. Basel: S. Karger AG, 2022, roč. 51, č. 3, s. 296-303. ISSN 1015-9770. doi:10.1159/000519937.
Impact factor: 3.104 v roce 2021

37.    WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, et al.
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2022, roč. 40, č. 2, s. 280-286. ISSN 0278-0232. doi:10.1002/hon.2974. 
Impact factor: 4.850 v roce 2021

38.    DUFKOVÁ, Kristýna, Matěj BEZDÍČEK, Kristina CUPROVA, et al.
Sequencing Independent Molecular Typing of Staphylococcus aureus Isolates: Approach for Infection Control and Clonal Characterization.
Microbiology Spectrum. WASHINGTON: American Society for Microbiology, 2022, roč. 10, č. 1, s. 1-10. ISSN 2165-0497. doi:10.1128/spectrum.01817-21.
Impact factor: 9.043 v roce 2021

39.    BURKOŇ, Petr, Jan TRNA, Marek SLÁVIK, et al.
Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration.
Biomedicines. Basel: MDPI, 2022, roč. 10, č. 10, s. 1-23. ISSN 2227-9059. doi:10.3390/biomedicines10102480. 
Impact factor: 4.757 v roce 2021

40.    IVANOV, Vladimir, Su-Peng YEH, Jiří MAYER, et al.
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Future Oncology. London: Future Medicine Ltd., 2022, roč. 18, č. 26, s. 2879-2889. ISSN 1479-6694. doi:10.2217/fon-2022-0450.
Impact factor: 3.674 v roce 2021

41.    ARPÁŠ, Tomáš, Hana JELÍNKOVÁ, Štěpán HRABOVSKÝ, et al.
Very rare near-haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR-T therapy in 19-year-old male patient.
CLINICAL CASE REPORTS. ENGLAND: WILEY, 2022, roč. 10, č. 3, s. 1-5. ISSN 2050-0904. doi:10.1002/ccr3.5545. 

42.    SANDECKÁ, Viera, Luděk POUR, Ivan ŠPIČKA, et al.
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Neoplasma. BRATISLAVA: AEPRESS SRO, 2022, roč. 69, č. 6, s. 1474-1479. ISSN 0028-2685. doi:10.4149/neo_2022_220813N827. 
Impact factor: 3.409 v roce 2021

43.    KREJČÍ, Martin, Zdeněk ADAM, Marta KREJČÍ, et al.
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity.
Neoplasma. BRATISLAVA: AEPRESS SRO, 2022, roč. 69, č. 5, s. 1008-1018. ISSN 0028-2685. doi:10.4149/neo_2022_220504N477. 
Impact factor: 3.409 v roce 2021

44.    BUSCA, Alessandro, Jon SALMANTON-GARCÍA, Paolo CORRADINI, et al.
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
Blood advances. AMSTERDAM: ELSEVIER, 2022, roč. 6, č. 7, s. 2427-2433. ISSN 2473-9529. doi:10.1182/bloodadvances.2021005616. 
Impact factor: 7.637 v roce 2021

45.    KRKOŠKA, Martin, Jana NEKVINDOVA, Kateřina NEVĚDĚLOVÁ, et al.
Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma.
Pharmacological Reports. KRAKOW: POLISH ACAD SCIENCES INST PHARMACOLOGY, 2022, roč. 74, č. 1, s. 148-158. ISSN 1734-1140. doi:10.1007/s43440-021-00338-9. info
Impact factor: 3.919 v roce 2021

46.    KRÁLOVÁ, Stanislava, Lenka DAVIDOVA-GERZOVA, Adam VALCEK, et al.
Paraphocaeicola brunensis gen. nov., sp. nov., Carrying Two Variants of nimB Resistance Gene from Bacteroides fragilis, and Caecibacteroides pullorum gen. nov., sp. nov., Two Novel Genera Isolated from Chicken Caeca.
Microbiology Spectrum. American Society for Microbiology, 2022, roč. 10, č. 1, s. 1-21. ISSN 2165-0497. doi:10.1128/spectrum.01954-21.
Impact factor: 9.043 v roce 2021

47.    KHIRSARIYA, PrashantKumar, Patrik POSPÍŠIL, Lukáš MAIER, et al.
Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
Journal of Medicinal Chemistry. Washington: American Chemical Society, 2022, roč. 65, č. 7, s. 5701-5723. ISSN 0022-2623. doi:10.1021/acs.jmedchem.1c02228. 
Impact factor: 8.039 v roce 2021

48.    ŘÍHOVÁ, Kamila, Monika DÚCKA, Iva STANICZKOVÁ ZAMBO, et al.
Transcription factor c-Myb: novel prognostic factor in osteosarcoma.
Clinical & Experimental Metastasis. Springer, 2022, roč. 39, č. 2, s. 375-390. ISSN 0262-0898. doi:10.1007/s10585-021-10145-4.
Impact factor: 4.510 v roce 2021

49.    DAVE, Zankruti, Olga VONDÁLOVÁ BLANÁŘOVÁ, Štěpán ČADA, et al.
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells.
Frontiers in Cell and Developmental Biology. Frontiers Media SA, 2022, roč. 10, February 2022, s. 1-11. ISSN 2296-634X. doi:10.3389/fcell.2022.838871. 
Impact factor: 6.081 v roce 2021

50.    SKALNÍKOVÁ, Magdalena, Kateřina STAŇO KOZUBÍK, Jakub TRIZULJAK, et al.
A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome.
International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, roč. 23, č. 2, s. 1-13. ISSN 1422-0067. doi:10.3390/ijms23020885.
Impact factor: 6.208 v roce 2021

51.    HOFERKOVÁ, Eva, Soňa KADÁKOVÁ a Marek MRÁZ.
In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.
CANCERS. SWITZERLAND: MDPI, 2022, roč. 14, č. 13, s. 3087-3107. ISSN 2072-6694. doi:10.3390/cancers14133087.
Impact factor: 6.575 v roce 2021

52.    MRÁZ, Marek.
Genetic mechanism for the loss of PRAME in B cell lymphomas.
Journal of Clinical Investigation. Ann Arbor: AMER SOC CLINICAL INVESTIGATION INC, 2022, roč. 132, č. 14, s. nestrankovano, 1 s. ISSN 0021-9738. doi:10.1172/JCI160983.
Impact factor: 19.456 v roce 2021

53.    URAZBAKHTIN, Shamil, Anastasia SMIRNOVA, Anastasiya VOLAKHAVA, et al.
The Absence of Retroelement Activity Is Characteristic for Childhood Acute Leukemias and Adult Acute Lymphoblastic Leukemia.
International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, roč. 23, č. 3, s. 1756-1768. ISSN 1422-0067. doi:10.3390/ijms23031756.
Impact factor: 6.208 v roce 2021

54.    ĎURINÍKOVÁ, Anna, Adam FOLTA, Filip PARDY, et al.
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
LEUKEMIA & LYMPHOMA. ABINGDON: TAYLOR & FRANCIS LTD, 2022, roč. 63, č. 13, s. 3237-3240. ISSN 1042-8194. doi:10.1080/10428194.2022.2116931. 
Impact factor: 2.996 v roce 2021
 

 

Publikace v impaktovaných periodicích 2021

1.    LEEKSMA, A. C., P. BALIAKAS, T. MOYSIADIS, et al.
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study.
Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2021, roč. 106, č. 1, s. 87-97. ISSN 0390-6078. doi:10.3324/haematol.2019.239947. 
Impact factor: 9.941 v roce 2020

2.    VREDE, S. W., W. J. VAN WEELDEN, N. C. M. VISSER, et al.
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Gynecologic Oncology. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2021, roč. 161, č. 3, s. 787-794. ISSN 0090-8258. doi:10.1016/j.ygyno.2021.03.031. 
Impact factor: 5.482 v roce 2020

3.    HOLCAKOVA, Jitka, Martin BARTOSIK, Milan ANTON, et al.
New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers.
Cancers. BASEL: MDPI, 2021, roč. 13, č. 24, s. 1-23. ISSN 2072-6694. doi:10.3390/cancers13246339.
Impact factor: 6.639 v roce 2020

4.    ŠUSTKOVÁ, Zuzana, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ a Jiří MAYER.
How to select older patients with acute myeloid leukemia fit for intensive treatment?
Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2021, roč. 39, č. 3, s. 151-161. ISSN 0278-0232. doi:10.1002/hon.2798.
Impact factor: 5.271 v roce 2020

5.    ŠEDOVÁ, Petra, Robert D. BROWN, Miroslav ZVOLSKY, et al.
Incidence of Stroke and Ischemic Stroke Subtypes: A Community-Based Study in Brno, Czech Republic.
Cerebrovascular Diseases. BASEL: KARGER, 2021, roč. 50, č. 1, s. 54-61. ISSN 1015-9770. doi:10.1159/000512180.
Impact factor: 2.762 v roce 2020

6.    FOLTA, Adam, Tomas JURCEK, Blanka KUBESOVA, et al.
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients.
LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2021, roč. 62, č. 5, s. 1239-1242. ISSN 1042-8194. doi:10.1080/10428194.2020.1861274. 
Impact factor: 3.280 v roce 2020

7.    MIKULKOVA, Zuzana, Gayane MANUKYAN, Peter TURCSANYI, et al.
Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks.
Nature Scientific Reports. London: NATURE RESEARCH, 2021, roč. 11, č. 1, s. 1-13. ISSN 2045-2322. doi:10.1038/s41598-020-79121-4. 
Impact factor: 4.379 v roce 2020

8.    KAYSER, S., R. K. HILLS, R. LANGOVA, et al.
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
British journal of haematology. England: Wiley-Blackwell, 2021, roč. 192, č. 5, s. 832-842. ISSN 0007-1048. doi:10.1111/bjh.17336.
Impact factor: 6.998 v roce 2020

9.    EID, Michal, Lenka OSTŘÍŽKOVÁ, Lumír KUNOVSKÝ, et al.
Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
Neoplasma. Bratislava: Slovak Academy of Sciences, 2021, roč. 68, č. 1, s. 1-9. ISSN 0028-2685. doi:10.4149/neo_2020_200408N372.
Impact factor: 2.575 v roce 2020

10.    JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, et al.
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Leukemia. London: Nature Publishing Group, 2021, roč. 36, č. 1, s. 288-291. ISSN 0887-6924. doi:10.1038/s41375-021-01343-w.
Impact factor: 11.528 v roce 2020

11.    TILLMANN, S., K. OLSCHOK, S. K. SCHRODER, et al.
The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.
Cancers. BASEL: MDPI, 2021, roč. 13, č. 16, s. 1-18. ISSN 2072-6694. doi:10.3390/cancers13164210.
Impact factor: 6.639 v roce 2020

12.    KUNOVSKÝ, Lumír, Petr DÍTĚ, Petr JABANDŽIEV, et al.
Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis.
Journal of Clinical Medicine. Basel: MDPI, 2021, roč. 10, č. 24, s. 1-22. ISSN 2077-0383. doi:10.3390/jcm10245779.
Impact factor: 4.241 v roce 2020

13.    RICHTER, J., A. LUBKING, S. SODERLUND, et al.
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 8, s. 2416-2418. ISSN 0887-6924. doi:10.1038/s41375-021-01173-w.
Impact factor: 11.528 v roce 2020

14.    RADOCHA, Jakub, Tomas JELINEK, Luděk POUR, et al.
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.
International Journal of Laboratory Hematology. MALDEN: WILEY-BLACKWELL, 2021, roč. 43, č. 5, s. "E244"-"E247", 4 s. ISSN 1751-5521. doi:10.1111/ijlh.13460. 
Impact factor: 2.877 v roce 2020

15.    ANDRAŠINA, Tomáš, Tomáš ROHAN, Jiří PÁNEK, et al.
The combination of endoluminal radiofrequency ablation and metal stent implantation for the treatment of malignant biliary stenosis-Randomized study.
European journal of radiology. Ireland: Elsevier Science Ireland Ltd, 2021, roč. 142, September 2021, s. 1-7. ISSN 0720-048X. doi:10.1016/j.ejrad.2021.109830. 
Impact factor: 3.528 v roce 2020

16.    ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ a Miroslav PENKA.
Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms.
Neoplasma. Bratislava: Slovenská akademie vied, 2021, roč. 68, č. 8, s. 1341-1350. ISSN 0028-2685. doi:10.4149/neo_2021_210729N1068. 
Impact factor: 2.575 v roce 2020

17.    KLEMPT, Petr, Ondrej BRZON, Martin KASNY, et al.
Distribution of SARS-CoV-2 Lineages in the Czech Republic, Analysis of Data from the First Year of the Pandemic.
Microorganisms. Basel: MDPI, 2021, roč. 9, č. 8, s. 1-12. ISSN 2076-2607. doi:10.3390/microorganisms9081671.
Impact factor: 4.128 v roce 2020

18.    ŽÁČKOVÁ, Daniela, Hana KLAMOVA, Petra BELOHLAVKOVA, et al.
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
LEUKEMIA & LYMPHOMA. LONDON: TAYLOR & FRANCIS, 2021, roč. 62, č. 1, s. 194-202. ISSN 1042-8194. doi:10.1080/10428194.2020.1827242.
Impact factor: 3.280 v roce 2020

19.    CRUCIANI, M., P. L. WHITE, C. MENGOLI, et al.
The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis.
Journal of Antimicrobial Chemotherapy. Oxford: Oxford University Press, 2021, roč. 76, č. 3, s. 635-638. ISSN 0305-7453. doi:10.1093/jac/dkaa498.
Impact factor: 5.790 v roce 2020

20.    MINARIK, J., T. PIKA, J. RADOCHA, et al.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
BMC Cancer. LONDON: BMC, 2021, roč. 21, č. 1, s. 1-13. ISSN 1471-2407. doi:10.1186/s12885-020-07732-1. 
Impact factor: 4.430 v roce 2020

21.    BAUMEISTER, Julian, Tiago MAIE, Nicolas CHATAIN, et al.
Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells.
Annals of Hematology. New York: Springer Verlag, 2021, roč. 100, č. 12, s. 2943-2956. ISSN 0939-5555. doi:10.1007/s00277-021-04615-8. 
Impact factor: 3.673 v roce 2020

22.    ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ a Miroslav PENKA.
The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms.
In vivo. Athens: International Institute of Anticancer Research, 2021, roč. 35, č. 6, s. 3345-3353. ISSN 0258-851X. doi:10.21873/invivo.12632.
Impact factor: 2.155 v roce 2020

23.    KOSTAL, Milan, Jiri SCHWARZ, Petra OVESNÁ, Miroslav PENKA a Petr DULICEK.
Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS. DORDRECHT: SPRINGER, 2021, roč. 51, č. 1, s. 112-119. ISSN 0929-5305. doi:10.1007/s11239-020-02175-8. 
Impact factor: 2.300 v roce 2020

24.    WEELDEN, Willem Janvan, Casper REIJNEN, Heidi V.N. KÜSTERS-VANDEVELDE, et al.
The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study.
Human Pathology. Philadelphia: Elseveir, 2021, roč. 109, March 2021, s. 80-91. ISSN 0046-8177. doi:10.1016/j.humpath.2020.12.003.
Impact factor: 3.466 v roce 2020

25.    LEJDAROVÁ, Hana, Rita PACASOVA, Lenka TESAROVA, et al.
Cryopreserved buffy-coat-derived platelets reconstituted in platelet additive solution: A safe and available product with sufficient haemostatic effectiveness.
Doleček Martin. TRANSFUSION AND APHERESIS SCIENCE. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2021, roč. 60, č. 3, s. 1-7. ISSN 1473-0502. doi:10.1016/j.transci.2021.103110.
Impact factor: 1.764 v roce 2020

26.    VINKLEROVÁ, Petra, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, et al.
Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer.
Healthcare. Basel: MDPI, 2021, roč. 9, č. 7, s. 1-9. ISSN 2227-9032. doi:10.3390/healthcare9070902.
Impact factor: 2.645 v roce 2020

27.    KREJČÍ, Marta, Luděk POUR, Zdeněk ADAM, et al.
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience.
Annals of hematology. New York: Springer Verlag, 2021, roč. 100, č. 10, s. 2541-2546. ISSN 0939-5555. doi:10.1007/s00277-021-04594-w.
Impact factor: 3.673 v roce 2020

28.    CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, et al.
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 12, s. 3444-3454. ISSN 0887-6924. doi:10.1038/s41375-021-01450-8.
Impact factor: 11.528 v roce 2020

29.    ZÁVACKÁ, Kristýna a Karla PLEVOVÁ.
Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability.
Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2021, roč. 11, November 2021, s. 1-9. ISSN 2234-943X. doi:10.3389/fonc.2021.771664. 
Impact factor: 6.244 v roce 2020

30.    GLEIXNER, K. V., Y. FILIK, D. BERGER, et al.
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1(T315I)-compound mutations.
AMERICAN JOURNAL OF CANCER RESEARCH. MADISON: E-CENTURY PUBLISHING CORP, 2021, roč. 11, č. 9, s. 4470-4484. ISSN 2156-6976. 
Impact factor: 6.166 v roce 2020

31.    PEHALOVÁ, Lucie, Denisa KREJČÍ, Jana HALÁMKOVÁ, et al.
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients.
Cancer Epidemiology. Oxford: Elsevier, 2021, roč. 72, June 2021, s. 1-8. ISSN 1877-7821. doi:10.1016/j.canep.2021.101929. 
Impact factor: 2.984 v roce 2020

32.    LIPOVÝ, Břetislav, Filip RAŠKA, Iva KOCMANOVA, et al.
Trichoderma longibrachiatum and Aspergillus fischeri Infection as a Cause of Skin Graft Failure in a Patient with Critical Burns after Liver Transplantation.
Journal of Fungi. BASEL: MDPI, 2021, roč. 7, č. 6, s. 1-10. ISSN 2309-608X. doi:10.3390/jof7060487.
Impact factor: 5.816 v roce 2020

33.    STASIK, S., J. N. ECKARDT, M. KRAMER, et al.
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
BLOOD ADVANCES. WASHINGTON: AMER SOC HEMATOLOGY, 2021, roč. 5, č. 17, s. 3279-3289. ISSN 2473-9529. doi:10.1182/bloodadvances.2021004631. 
Impact factor: 6.686 v roce 2020

34.    SEDLAR, Karel, Marketa NYKRYNOVA, Matěj BEZDÍČEK, et al.
Diversity and Evolution of Clostridium beijerinckii and Complete Genome of the Type Strain DSM 791(T).
PROCESSES. Vilnius: MDPI, 2021, roč. 9, č. 7, s. 1-16. ISSN 2227-9717. doi:10.3390/pr9071196. 
Impact factor: 2.847 v roce 2020

35.    ECKARDT, J. N., S. STASIK, M. KRAMER, et al.
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.
Cancers. BASEL: MDPI, 2021, roč. 13, č. 9, s. 1-15. ISSN 2072-6694. doi:10.3390/cancers13092095. 
Impact factor: 6.639 v roce 2020

36.    BEZDÍČEK, Matěj, Marketa NYKRYNOVA, Karel SEDLAR, et al.
Rapid high-resolution melting genotyping scheme for Escherichia coli based on MLST derived single nucleotide polymorphisms.
Scientific Reports. London: Nature Research, 2021, roč. 11, č. 1, s. "16572", 11 s. ISSN 2045-2322. doi:10.1038/s41598-021-96148-3. 
Impact factor: 4.379 v roce 2020

37.    EID, Michal, Paraskevi KAROUSI, Lumír KUNOVSKÝ, et al.
The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma.
Biomedicines. Basel: MDPI, 2021, roč. 9, č. 10, s. 1-17. ISSN 2227-9059. doi:10.3390/biomedicines9101468.
Impact factor: 6.081 v roce 2020

38.    BORSKÝ, Marek, Viera HRABČÁKOVÁ, Jitka NOVOTNÁ, et al.
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2021, roč. 111, December 2021, s. 1-11. ISSN 0145-2126. doi:10.1016/j.leukres.2021.106684.
Impact factor: 3.156 v roce 2020

39.    BAŤALÍK, Ladislav, Petr WINNIGE, Filip DOSBABA, Daniela VLAŽNÁ a Andrea JANÍKOVÁ.
Home-Based Aerobic and Resistance Exercise Interventions in Cancer Patients and Survivors: A Systematic Review.
Cancers. Basel: MDPI, 2021, roč. 13, č. 8, s. 1-17. ISSN 2072-6694. doi:10.3390/cancers13081915. 
Impact factor: 6.639 v roce 2020

40.    PROCHÁZKOVÁ, Dagmar, Romana BORSKÁ, Lenka FAJKUSOVÁ, et al.
Two Novel Mutations in the JAG1 Gene in Pediatric Patients with Alagille Syndrome: The First Case Series in Czech Republic.
Diagnostics. Basel: MDPI, 2021, roč. 11, č. 6, s. 1-7. ISSN 2075-4418. doi:10.3390/diagnostics11060983. 
Impact factor: 3.706 v roce 2020

41.    WEINBERGEROVÁ, Barbora, Jiří MAYER, Štěpán HRABOVSKÝ, et al.
COVID-19's natural course among ambulatory monitored outpatients.
Nature Scientific Reports. London: NATURE RESEARCH, 2021, roč. 11, č. 1, s. 1-16. ISSN 2045-2322. doi:10.1038/s41598-021-89545-1.
Impact factor: 4.379 v roce 2020

42.    BEDNAŘÍKOVÁ, Markéta, Petra VINKLEROVÁ, Jana GOTTWALDOVÁ, et al.
The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer.
Journal of Clinical Medicine. Basel: MDPI, 2021, roč. 10, č. 12, s. 1-14. ISSN 2077-0383. doi:10.3390/jcm10122640.
Impact factor: 4.241 v roce 2020

43.    PAGANO, L., J. SALMANTON-GARCIA, F. MARCHESI, et al.
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2021, roč. 14, č. 1, s. 1-15. ISSN 1756-8722. doi:10.1186/s13045-021-01177-0. 
Impact factor: 17.388 v roce 2020

44.    WEINBERGEROVÁ, Barbora, Jiří MAYER, Tomáš KABUT, et al.
Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2021, roč. 39, č. 5, s. 715-720. ISSN 0278-0232. doi:10.1002/hon.2908.
Impact factor: 5.271 v roce 2020

45.    FORNEROD, M., J. MA, S. NOORT, et al.
Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators.
BLOOD CANCER DISCOVERY. PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021, roč. 2, č. 6, s. 586-599. ISSN 2643-3230. doi:10.1158/2643-3230.BCD-21-0049.

46.    HERMANKOVA, Kristyna, Xenie KOURILOVA, Iva PERNICOVA, et al.
Complete Genome Sequence of the Type Strain Tepidimonas taiwanensis LMG 22826T, a Thermophilic Alkaline Protease and Polyhydroxyalkanoate Producer.
GENOME BIOLOGY AND EVOLUTION. OXFORD: OXFORD UNIV PRESS, 2021, roč. 13, č. 12, s. 1-5. ISSN 1759-6653. doi:10.1093/gbe/evab280. 
Impact factor: 3.416 v roce 2020

47.    KRÁLOVÁ, Stanislava, Hans-Jürgen BUSSE, Matěj BEZDÍČEK, et al.
Flavobacterium flabelliforme sp. nov. and Flavobacterium geliluteum sp. nov., Two Multidrug-Resistant Psychrotrophic Species Isolated From Antarctica.
Frontiers in Microbiology. Frontiers Media S.A., 2021, roč. 12, October, s. 729977-729996. ISSN 1664-302X. doi:10.3389/fmicb.2021.729977. 
Impact factor: 5.640 v roce 2020

48.    SHARMA, Sonali, Gabriela MLADONICKÁ PAVLASOVÁ, et al.
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors.
Blood. Washington, DC: American Society of Hematology, 2021, roč. 137, č. 18, s. 2481-2494. ISSN 0006-4971. doi:10.1182/blood.2020005627.
Impact factor: 22.113 v roce 2020

49.    HRABOVSKÝ, Štěpán, Zuzana VRZALOVÁ, Jiří ŠTIKA, et al.
Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype.
Acta Oncologica. ABINGDON: TAYLOR & FRANCIS LTD, 2021, roč. 60, č. 6, s. 760-770. ISSN 0284-186X. doi:10.1080/0284186X.2021.1900908. 
Impact factor: 4.089 v roce 2020

50.    ROMŽOVÁ, Marianna, Dagmar SMITALOVÁ, Jakub HYNŠT, et al.
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
British journal of haematology. Hoboken: Wiley-Blackwell, 2021, roč. 194, č. 3, s. 604-612. ISSN 0007-1048. doi:10.1111/bjh.17659. 
Impact factor: 6.998 v roce 2020

51.    DOFFE, Flora, Vincent CARBONNIER, Manon TISSIER, et al.
Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.
Cell Death and Differentiation. London: Springer Nature, 2021, roč. 28, č. 5, s. 1477-1492. ISSN 1350-9047. doi:10.1038/s41418-020-00672-0. info
Impact factor: 15.828 v roce 2020

52.    LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, et al.
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 5, s. 1500-1505. ISSN 0887-6924. doi:10.1038/s41375-020-01093-1. 
Impact factor: 11.528 v roce 2020

53.    LEDEREROVÁ, Aneta, Lenka DOSTÁLOVÁ, Veronika KOZLOVÁ, et al.
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro.
Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2021, roč. 9, č. 8, s. 1-8. ISSN 2051-1426. doi:10.1136/jitc-2021-002352. 
Impact factor: 13.751 v roce 2020

54.    ŠANDOVÁ, Veronika, Gabriela MLADONICKÁ PAVLASOVÁ, Václav ŠEDA, et al.
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K delta inhibitor idelalisib.
haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2021, roč. 106, č. 11, s. 2995-2999. ISSN 0390-6078. doi:10.3324/haematol.2021.278644.
Impact factor: 9.941 v roce 2020

55.    GEMENETZI, K., F. PSOMOPOULOS, A. A. CARRILES, et al.
Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
Blood. Washington DC, USA: American Society of Hematology, 2021, roč. 137, č. 14, s. 1895-1904. ISSN 0006-4971. doi:10.1182/blood.2020005216.
Impact factor: 22.113 v roce 2020

56.    STAŇO KOZUBÍK, Kateřina, Lenka RADOVÁ, Kamila RÉBLOVÁ, et al.
Functional analysis of germlineETV6 W380Rmutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia.
Platelets. PHILADELPHIA: TAYLOR & FRANCIS INC, 2021, roč. 32, č. 6, s. 838-841. ISSN 0953-7104. doi:10.1080/09537104.2020.1802416. 
Impact factor: 3.862 v roce 2020

57.    HYNŠT, Jakub, Veronika NAVRKALOVÁ, Karol PÁL a Šárka POSPÍŠILOVÁ.
Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application.
PeerJ. London: PEERJ INC, 2021, roč. 9, MAR 2021, s. 1-29. ISSN 2167-8359. doi:10.7717/peerj.10897. 
Impact factor: 2.984 v roce 2020

58.    SVOZILOVÁ, Hana, Z. PLICHTA, V. PROKS, et al.
RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model.
International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2021, roč. 22, č. 5, s. 2376-2392. ISSN 1422-0067. doi:10.3390/ijms22052376. info
Impact factor: 5.923 v roce 2020

59.    MALČÍKOVÁ, Jitka, Šárka PAVLOVÁ, Barbara KUNT VONKOVÁ, et al.
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Blood. Washington DC, USA: American Society of Hematology, 2021, roč. 138, č. 25, s. 2670-2685. ISSN 0006-4971. doi:10.1182/blood.2020009530.
Impact factor: 22.113 v roce 2020

60.    NAVRKALOVÁ, Veronika, Karla PLEVOVÁ, Jakub HYNŠT, et al.
LYmphoid NeXt-Generation Sequencing (LYNX) Panel A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies.
The journal of molecular diagnostics. Bethesda, MD: American Society for Investigative Pathology/Association for Molecular Pathology, 2021, roč. 23, č. 8, s. 959-974. ISSN 1525-1578. doi:10.1016/j.jmoldx.2021.05.007. 
Impact factor: 5.568 v roce 2020

61.    NTOUFA, S., M. GEROUSI, S. LAIDOU, et al.
RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia.
BLOOD ADVANCES. WASHINGTON: AMER SOC HEMATOLOGY, 2021, roč. 5, č. 13, s. 2788-2792. ISSN 2473-9529. doi:10.1182/bloodadvances.2020001717.
Impact factor: 6.686 v roce 2020

62.    ŠEDA, Václav, Eva VOJÁČKOVÁ, Laura ONDRIŠOVÁ, et al.
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Blood. Washington DC, USA: American Society of Hematology, 2021, roč. 138, č. 9, s. 758-772. ISSN 0006-4971. doi:10.1182/blood.2020008101.
Impact factor: 22.113 v roce 2020

63.    AGATHANGELIDIS, A., A. CHATZIDIMITRIOU, K. GEMENETZI, et al.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Blood. Washington DC, USA: American Society of Hematology, 2021, roč. 137, č. 10, s. 1365-1376. ISSN 0006-4971. doi:10.1182/blood.2020007039. info
Impact factor: 22.113 v roce 2020

64.    TAUŠ, Petr, Šárka POSPÍŠILOVÁ a Karla PLEVOVÁ.
Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways.
Frontiers in Genetics. Laussane: FRONTIERS MEDIA SA, 2021, roč. 12, JUN, s. 627964-627973. ISSN 1664-8021. doi:10.3389/fgene.2021.627964. info
Impact factor: 4.599 v roce 2020

65.    SMITALOVÁ, Dagmar, D. DVORAKOVA, Zdeněk RÁČIL a Marianna ROMŽOVÁ.
Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays.
Practical Laboratory Medicine. AMSTERDAM: ELSEVIER, 2021, roč. 25, MAY, s. nestrankovano, 6 s. ISSN 2352-5517. doi:10.1016/j.plabm.2021.e00210.